Last reviewed · How we verify
NCT05410938
Intraperitoneal Chemotherapy Versus Triweekly Chemotherapy
trial testing Chemotherapy in Intraperitoneal Chemotherapy, Bevacizumab, Ovarian Cancer in 59 participants. Completed in 1 May 2023.
1 May 2023
Quick facts
| Lead sponsor | Far Eastern Memorial Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 59 |
| Start date | 6 June 2022 |
| Primary completion | 1 May 2023 |
| Estimated completion | 1 May 2023 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- Chemotherapy (chemotherapy) — full drug profile →
Conditions studied
- Intraperitoneal Chemotherapy, Bevacizumab, Ovarian Cancer — all drugs for Intraperitoneal Chemotherapy, Bevacizumab, Ovarian Cancer →
Sponsor
Far Eastern Memorial Hospital
Who can join
20 and older, female only, with Intraperitoneal Chemotherapy, Bevacizumab, Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The combination of paclitaxel and carboplatin is the standard first-line chemotherapy for ovarian cancer as recommended by the NCCN Guidelines for Epithelial Ovarian Cancer, and is conventionally given via intravenous route every three weeks. The addition of target therapy (bevacizumab) has shown to improve progression free survival but not overall survival. Several trials have also demonstrated a clinically significant survival advantage associated with intraperitoneal chemotherapy compared to intravenous chemotherapy, and the best outcomes are consistently seen for patients who have no residual disease. This study aims to compare triweekly chemotherapy with bevacizumab versus intraperitoneal chemotherapy in patients with advanced stage ovarian cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05410938
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Chemotherapy
Trials testing the same drug.
- NCT07391774 — Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribocic · Phase 3 · not yet recruiting
- NCT07476287 — Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult · Phase 2 · recruiting
- NCT07392892 — A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer · Phase 2, PHASE3 · recruiting
- NCT07288034 — Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatmen · Phase 2 · recruiting
- NCT07078604 — A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negati · Phase 2 · recruiting
Other Far Eastern Memorial Hospital trials
Trials by the same sponsor.
- NCT07385976 — The Role of Blood Perfusion in Cervical Cancer, Cervical Intraepithelial Neoplasm and Ovarian Cancer Patients · not yet recruiting
- NCT07107542 — Exploring the Relationship Between Mini-Clinical Evaluation Exercise (Mini-CEX) and Entrustable Professional Activities · not yet recruiting
- NCT07114653 — The Role of POLE Mutation in High Risk Endometrial Cancer. · recruiting
- NCT07105345 — Exploring Efficacy of Multi-Mode Cognitive Processing Therapy (CPT) for PTSD · NA · recruiting
- NCT07110350 — Clinical Outcomes of Non-Indicated Staged Laparotomies in Abdominal Trauma · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05410938 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Far Eastern Memorial Hospital
- Last refreshed: 10 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05410938.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing